Antibodies for
Immunohistochemistry
Pneumocystis jiroveci (carinii) (3F6)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45325 IMPATH Pneumocystis jirovecci RTU M (3F6)
50 Tests
44373 Pneumocystis jirovecci (carini) RTU M (3F6)
7 ml Ready To Use
44765 Pneumocystis jirovecci (carini) 0,1 M (3F6)
100 µl liquid Concentrated
44766 Pneumocystis jirovecci (carini) 1 M (3F6)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Membranous
Control
P.jiroveci Infected Tissue
Stability
Up to 36 mo. at 2-8°C
Isotype
IgM/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP 2-step
Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Pneumocystis jiroveci (carinii) is a fungal organism which is detected in human tissues (typically in lung in immunocompromised patients) in the
trophozoite stage. Anti-pneumocystis jiroveci reacts with an epitope on the organism which is resistant to formalin, picric acid, paraffin, as well
as alchohol and xylene. No cross-reactivity has been demonstrated with other fungi or parasitic organisms.
Reference
1. Silverberg SG, et al. Principles and Practice of Surgical Pathology and Cytopathology, 3rd edition. 1997; 182-185.
2. Linder E, et al. J Immunol Methods. 1987; 98:57-62.
3. Elvin KM, et al. L Br Med J. 1988; 297:381-4.
4. Radio SJ, et al. Modern Pathol. 1990; 3:462-9.
204
